DETECT-HCC-ESLD

A X-ray image of a liver
Photographer: SEBASTIAN KAULITZKI/SCIENCE PHOT

A comparative study of MRI and ultrasound for detection of primary hepatocellular carcinoma, body composition and risk factors for decompensation in liver cirrhosis (DETECT-HCC-ESLD)

In liver cirrhosis, sometimes referred to as hepatic fibrosis, there is an increased risk of several serious complications such as abdominal fluid accumulation (ascites), liver cancer, and muscle mass loss. As patients with liver cirrhosis are at risk of developing these complications, they are closely monitored using various methods including ultrasound, gastroscopy, and regular visits to liver clinics. This study evaluates how effectively these complications (ascites, liver cancer, and muscle mass loss) can be detected and monitored, comparing ultrasound with a shortened MRI scan, conducted every six months as part of liver cancer surveillance. Additionally, blood samples are analysed to identify proteins, genetic predispositions, or gene expressions that may be linked to the future risk of developing liver disease complications or detecting them at an early stage.
This clinical trial is conducted at more than ten hospitals in collaboration with Linköping University, which is the main sponsor and coordinator. The study will include 600 patients from various regions in Sweden, Iceland, and Finland.
The aim is to improve care for patients with liver cirrhosis, enabling more patients to be cured of liver cancer and reducing the number who develop severe complications related to cirrhosis. The study will also provide new tools for the pharmaceutical industry to better design future drug trials.

En bild på Detect forskargrupp


Study Design

Matrix
Data examinations

ContaCt

Organisation